<bill session="111" type="s" number="501" updated="2022-02-03T06:05:12Z">
  <state datetime="2009-02-26">REFERRED</state>
  <status>
    <introduced datetime="2009-02-26"/>
  </status>
  <introduced datetime="2009-02-26"/>
  <titles>
    <title type="short" as="introduced">Fair Prescription Drug Competition Act</title>
    <title type="display">Fair Prescription Drug Competition Act</title>
    <title type="official" as="introduced">A bill to amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.</title>
  </titles>
  <sponsor bioguide_id="R000361"/>
  <cosponsors>
    <cosponsor bioguide_id="B000944" joined="2009-02-26"/>
    <cosponsor bioguide_id="I000025" joined="2009-02-26"/>
    <cosponsor bioguide_id="K000305" joined="2009-02-26"/>
    <cosponsor bioguide_id="L000174" joined="2009-02-26"/>
    <cosponsor bioguide_id="S000148" joined="2009-02-26"/>
    <cosponsor bioguide_id="S001181" joined="2009-02-27"/>
    <cosponsor bioguide_id="S000770" joined="2009-03-03"/>
  </cosponsors>
  <actions>
    <action datetime="2009-02-26">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2009-02-26">
      <text>Sponsor introductory remarks on measure.</text>
      <reference ref="CR S2569-2570"/>
    </action>
    <action datetime="2009-02-26" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2009-03-21T14:25:09Z" status="Introduced in Senate">Fair Prescription Drug Competition Act - Amends the Federal Food, Drug, and Cosmetic Act to prohibit a holder of a new, approved drug application from commencing to manufacture, market, sell, or distribute a generic version of such drug from the time of the receipt of notice from the generic manufacturer that an abbreviated new drug application has been submitted for approval until the expiration or forfeiture of the exclusivity period granted to the generic manufacturer.</summary>
</bill>
